1
Russian Respiratory Society
Federal clinical
recommendations for diagnosis and
treatment
chronic obstructive disease
lungs
2014

2
Team of authors
Chuchalin Alexander Grigorievich Director of the Federal State Budgetary Institution "Research Institute of Pulmonology" FMBA
Russia, Chairman of the Board of the Russian Respiratory Society, Chief Freelance Specialist Pulmonologist
Ministry of Health of the Russian Federation, Academician of the Russian Academy of Medical Sciences, Professor, Doctor of Medical Sciences
Aisanov Zaurbek Ramazanovich
Head of the Department of Clinical Physiology and Clinical Research, FSBI "Research Institute of Pulmonology" of the Federal Medical and Biological Agency of Russia, Professor
Avdeev Sergey Nikolaevich
Deputy Director for Research, Head of the Clinical Department of the Federal State Budgetary Institution "Research Institute of Pulmonology" of the Federal Medical and Biological Agency of Russia, Professor, MD
Belevsky Andrey
Stanislavovich
Professor of the Department of Pulmonology, SBEI HPE
Russian National Research Medical University named after N.I. Pirogova, head of the rehabilitation laboratory
FGBU "Research Institute of Pulmonology" FMBA of Russia
, professor, d.m.s.
Leshchenko Igor Viktorovich
Professor of the Department of Phthisiology and Pulmonology, USMU, Chief Freelance Pulmonologist of the Ministry of Health
Sverdlovsk Region and the Health Department of Yekaterinburg, scientific director of the clinic "Medical Association" New Hospital ", professor, MD, Honored Doctor of Russia,
Meshcheryakova Natalya Nikolaevna
Associate Professor of the Department of Pulmonology, SBEI HPE Russian National Research Medical University named after N.I. Pirogova, Leading Researcher, Rehabilitation Laboratory
FSBI "Research Institute of Pulmonology" FMBA of Russia, Ph.D.
Ovcharenko Svetlana Ivanovna
Professor of the Department of Faculty Therapy No. 1 of the Faculty of Medicine, First State Budgetary Educational Institution of Higher Professional Education
MGMU them. THEM. Sechenov, professor, MD,
Honored Doctor of the Russian Federation
Shmelev Evgeny Ivanovich
Head of the Department of Differential Diagnosis of Tuberculosis, TsNIIT RAMS, Dr. med. Sci., Professor, Doctor of Medical Sciences, an honored worker of science of the Russian Federation.

3
TABLE OF CONTENTS
1.
Methodology
4
2.
Definition of COPD and epidemiology
6
3.
Clinical picture COPD
8
4.
Diagnostic principles
11
5.
Functional tests in diagnostics and monitoring
14
course of COPD
6.
Differential diagnosis of COPD
18
7.
Modern classification of COPD. Integrated
20
assessment of the severity of the current.
8.
Therapy for stable COPD
24
9.
Exacerbation of COPD
29
10.
Therapy for exacerbation of COPD
31
11.
COPD and comorbidities
34
12.
Rehabilitation and patient education
36

4
1. Methodology
Methods used to collect/select evidence:
search in electronic databases.
Description of the methods used to collect/select evidence: the evidence base for the recommendations are the publications included in
Cochrane Library, EMBASE and MEDLINE databases. The search depth was 5 years.
Methods used to assess the quality and strength of evidence:

Expert consensus;

Significance assessment in accordance with the rating scheme (see Table 1).
Table 1. Rating scheme for assessing the strength of recommendations.
Levels
evidence
Description
1++
High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or
RCT with very low risk of bias
1+
Qualitatively conducted meta-analyses, systematic, or
RCT with low risk of bias
1-
Meta-analyses, systematic, or RCTs with a high risk of bias
2++
High-quality systematic reviews of case-control or cohort studies.
High-quality reviews of case-control or cohort studies with very low risk of confounding effects or bias and moderate likelihood of causation
2+
Well-conducted case-control or cohort studies with moderate risk of confounding effects or bias and moderate likelihood of causation
2-
Case-control or cohort studies with a high risk of confounding effects or biases and an average likelihood of causation
3
Non-analytic studies (eg, case reports, case series)
4
Expert opinion
Methods used to analyze the evidence:

Reviews of published meta-analyses;

Systematic reviews with tables of evidence.
Description of the methods used to analyze the evidence:
When selecting publications as potential sources of evidence, the methodology used in each study is reviewed to ensure its validity. The outcome of the study influences the level of evidence assigned to the publication, which in turn affects the strength of the recommendations that follow from it.

5
The methodological study is based on several key questions that focus on those features of the study design that have a significant impact on the validity of the results and conclusions. These key questions may vary depending on the types of studies and the questionnaires used to standardize the publication evaluation process. The recommendations used the MERGE questionnaire developed by
Department of Health New South Wales. This questionnaire is designed to be assessed in detail and adapted according to the requirements
Russian Respiratory Society (RRS) in order to maintain an optimal balance between methodological rigor and the possibility practical application.
The evaluation process, of course, can be affected by the subjective factor.
To minimize potential errors, each study was evaluated independently, ie. at least two independent members of the working group.
Any differences in assessments were already discussed by the entire group.
If it was impossible to reach a consensus, an independent expert was involved.
Evidence tables:
Evidence tables were filled in by members of the working group.
Methods used to formulate recommendations:
Expert consensus.
Table 2. Rating scheme for assessing the strength of recommendations
Strength
Description
BUT
At least one meta-analysis, systematic review, or RCT rated 1++, directly applicable to the target population and demonstrating robustness of results, or body of evidence including study results rated 1+, directly applicable to the target population, and demonstrating overall robustness results
AT
A body of evidence that includes results from studies rated 2++ that are directly applicable to the target population and demonstrate overall robustness of results, or extrapolated evidence from studies rated 1++ or 1+
FROM
A body of evidence that includes results from studies rated as 2+ that are directly applicable to the target population and demonstrate overall consistency of results; or extrapolated evidence from studies rated 2++
D
Level 3 or 4 evidence; or extrapolated evidence from studies rated 2+
Good Practice Points (GPPs):
The recommended good practice is based on the clinical experience of the members of the Guideline Development Working Group.
Economic analysis:

6
Cost analysis was not performed and publications on pharmacoeconomics were not analyzed.
Recommendation validation method:

External peer review;

Internal peer review.
Description of the recommendation validation method:
These draft recommendations have been peer-reviewed by independent experts who were asked to comment primarily on the extent to which the interpretation of the evidence underlying the recommendations is understandable.
Comments were received from primary care physicians and district therapists regarding the intelligibility of the presentation of recommendations and their assessment of the importance of recommendations as a working tool in everyday practice.
The draft was also sent to a non-medical reviewer for comments from a patient perspective.
The comments received from the experts were carefully systematized and discussed by the chair and members of the working group. Each item was discussed and the resulting changes to the recommendations were recorded. If no changes were made, then the reasons for refusing to make changes were recorded.
Consultation and expert assessment:
The preliminary version was put up for public discussion on the site.
PPO so that non-congress participants have the opportunity to participate in the discussion and improvement of the recommendations.
The draft recommendations were also reviewed by independent experts, who were asked to comment, first of all, on the clarity and accuracy of the interpretation of the evidence base underlying the recommendations.
Working group:
For the final revision and quality control, the recommendations were re-analyzed by the members of the working group, who came to the conclusion that all the comments and comments of the experts were taken into account, the risk of systematic errors in the development of recommendations was minimized.
Key recommendations:
Strength of recommendations (A – D), levels of evidence (1++, 1+, 1-, 2++, 2+, 2-, 3, 4) and indicators of good practice - good practice points (GPPs) are given when presenting the text recommendations.
2. Definition of COPD and epidemiology
Definition
COPD is a preventable and treatable disease
characterized by persistent airspeed limitation
flow, which is usually progressive and associated with severe chronic
inflammatory response of the lungs to the action of pathogenic particles or gases.
In some patients, exacerbations and comorbidities can affect
overall severity of COPD (GOLD 2014).
Traditionally, COPD combines chronic bronchitis and emphysema.
Chronic bronchitis is usually defined clinically as the presence of a cough with sputum production for at least 3 months over a subsequent 2 years.

7
Emphysema is defined morphologically as the presence of permanent enlargement respiratory tract distal to the terminal bronchioles, associated with destruction of the walls of the alveoli, not associated with fibrosis.
In patients with COPD, both conditions are most often present, and in some cases it is quite difficult to clinically distinguish them into early stages diseases.
The concept of COPD does not include bronchial asthma and other diseases associated with poorly reversible bronchial obstruction (cystic fibrosis, bronchiectasis, bronchiolitis obliterans).
Epidemiology
Prevalence
COPD is currently a global problem. In some parts of the world the prevalence of COPD is very high (over 20% in Chile), in others it is less (about 6% in Mexico). The reasons for this variability are differences in the way of life of people, their behavior and contact with various damaging agents.
One of the Global Studies (the BOLD project) provided a unique opportunity to estimate the prevalence of COPD using standardized questionnaires and pulmonary function tests in populations of adults over 40 years of age in both developed and developing countries. Prevalence
COPD stage II and above (GOLD 2008), according to the BOLD study, among people over 40 years of age was 10.1±4.8%; including for men - 11.8±7.9% and for women - 8.5±5.8%. According to an epidemiological study on the prevalence of COPD in the Samara region (residents aged 30 years and older), the prevalence of COPD in the total sample was 14.5% (men -18.7%, women - 11.2%). According to the results of another Russian study conducted in the Irkutsk region, the prevalence of COPD in people over 18 years of age among the urban population was 3.1%, among the rural

6,6 %.
The prevalence of COPD increased with age: in the age group from 50 to
69 years old, 10.1% of men in the city and 22.6%

in the countryside. Almost every second man over the age of 70 living in rural areas has been diagnosed with COPD.
Mortality
According to WHO, COPD is currently the 4th leading cause of death in the world. Approximately 2.75 million people die each year from COPD, which is
4.8% of all causes of death. In Europe, mortality from COPD varies considerably, from
0.20 per 100,000 population in Greece, Sweden, Iceland and Norway, up to 80 per 100,000 in Ukraine and Romania.
Between 1990 and 2000 mortality from cardiovascular diseases in general and from stroke decreased by 19.9% ​​and 6.9%, respectively, while mortality from COPD increased by 25.5%. Especially pronounced increase in mortality from
COPD is noted among women.
Predictors of lethality in patients with COPD are such factors as the severity of bronchial obstruction, nutritional status (body mass index), physical endurance according to the 6-minute walk test and the severity of shortness of breath, the frequency and severity of exacerbations, and pulmonary hypertension.
The main causes of death in patients with COPD are respiratory failure (RF), lung cancer, cardiovascular diseases and tumors of other localization.
Socioeconomic Importance of COPD
In developed countries, the total economic costs associated with COPD in the structure of lung diseases rank 2nd after lung cancer and 1st

8 in terms of direct costs, exceeding direct costs for bronchial asthma by 1.9 times.
The economic costs per patient associated with COPD are three times higher than those for a patient with bronchial asthma. The few reports of direct medical costs in COPD indicate that more than 80% of the material resources are for inpatient care for patients and less than 20% for outpatient care. It has been established that 73% of the costs are for 10% of patients with a severe course of the disease. The greatest economic damage is caused by the treatment of exacerbations of COPD. In Russia, the economic burden of COPD, taking into account indirect costs, including absenteeism (absenteeism) and presenteeism (less effective work due to poor health), is 24.1 billion rubles.
3. Clinical picture of COPD
Under the influence of risk factors (smoking - both active and passive, - exogenous pollutants, bioorganic fuels, etc.) COPD usually develops slowly and progresses gradually. The peculiarity of the clinical picture is that for a long time the disease proceeds without pronounced clinical manifestations (3, 4; D).
The first signs that patients seek medical attention are cough, often with sputum production and/or shortness of breath. These symptoms are most pronounced in the morning. During cold seasons, "frequent colds" occur.
This is the clinical picture of the onset of the disease,
which is regarded by the doctor as a manifestation of smoker's bronchitis, and the diagnosis of COPD at this stage is practically not made.
Chronic cough, usually the first symptom of COPD, is also often underestimated by patients, as it is considered an expected consequence of smoking and/or exposure to adverse environmental factors. Usually, patients produce a small amount of viscous sputum. An increase in cough and sputum production occurs most often in the winter months, during infectious exacerbations.
Shortness of breath - most important symptom COPD (4; D). It often serves as a reason for seeking medical help and the main reason that limits the patient's work activity. Assessment of the impact of shortness of breath on health status is carried out using the questionnaire of the British Medical Council
(MRC). At the onset, shortness of breath is noted with a relatively high level of physical activity, such as running on level ground or walking on stairs. As the disease progresses, dyspnea increases and may limit even daily activity, and later occurs at rest, forcing the patient to stay at home (Table 3). In addition, the assessment of dyspnea on the MRC scale is a sensitive tool for predicting the survival of patients with COPD.
Table 3 Medical Research Council Scale (MRC) dyspnea score
Dyspnea Scale.
Degree Severity
Description
0 no
I only feel short of breath when I exert myself heavily
1 easy
I get out of breath when I walk quickly on level ground or climb a gentle hill
2 medium
Because of my shortness of breath, I walk more slowly on level ground than people of the same age, or I stop breathing when I walk on level ground at my normal pace

9 3 heavy
I am out of breath after walking about 100m or after walking for a few minutes on level ground
4 very hard
I am too short of breath to leave the house or suffocate when I get dressed or undressed
When describing the COPD clinic, it is necessary to take into account the features characteristic of this particular disease: its subclinical onset, the absence of specific symptoms, and the steady progression of the disease.
The severity of symptoms varies depending on the phase of the course of the disease (stable course or exacerbation). Stable should be considered the condition in which the severity of symptoms does not change significantly over weeks or even months, and in this case, the progression of the disease can be detected only with long-term (6-12 months) dynamic monitoring of the patient.
Significant impact the clinical picture is affected by exacerbations of the disease - recurrent deterioration of the condition (lasting at least 2-3 days), accompanied by an increase in the intensity of symptoms and functional disorders. During an exacerbation, there is an increase in the severity of hyperinflation and the so-called. air traps in combination with a reduced expiratory flow, which leads to increased dyspnea, which is usually accompanied by the appearance or intensification of remote wheezing, a feeling of pressure in the chest, and a decrease in exercise tolerance.
In addition, there is an increase in the intensity of cough, changes
(increases or decreases sharply) the amount of sputum, the nature of its separation, color and viscosity. At the same time, performance indicators deteriorate external respiration and blood gases: speed indicators decrease (FEV
1
etc.), hypoxemia and even hypercapnia may occur.
The course of COPD is an alternation of a stable phase and an exacerbation of the disease, but in different people it proceeds differently. However, progression of COPD is common, especially if the patient continues to be exposed to inhaled pathogenic particles or gases.
The clinical picture of the disease also seriously depends on the phenotype of the disease and vice versa, the phenotype determines the characteristics of clinical manifestations.
COPD For many years, there has been a division of patients into emphysematous and bronchitis phenotypes.
Bronchitis type is characterized by a predominance of signs of bronchitis
(cough, sputum). Emphysema in this case is less pronounced. In the emphysematous type, on the contrary, emphysema is the leading pathological manifestation, shortness of breath prevails over cough. However, in clinical practice, it is very rare to distinguish the emphysematous or bronchitis phenotype of COPD in the so-called. "pure" form (it would be more correct to speak of a predominantly bronchitis or predominantly emphysematous phenotype of the disease).
The features of the phenotypes are presented in more detail in Table 4.

The classification of COPD (chronic obstructive pulmonary disease) is broad and includes a description of the most common stages of the disease and the variants in which it occurs. And although not all patients progress COPD according to the same scenario and not all can be identified as a certain type, the classification always remains relevant: most patients fit into it.

Stages of COPD

The first classification (spirographic classification of COPD), which determined the stages of COPD and their criteria, was proposed back in 1997 by a group of scientists united in a committee called the World COPD Initiative (on English name sounds "Global Initiative for chronic Obstructive Lung Disease" and is abbreviated as GOLD). According to her, there are four main stages, each of which is determined mainly by FEV - that is, the volume of forced expiratory flow in the first second:

• COPD 1 degree does not differ in special symptoms. The lumen of the bronchi is narrowed quite a bit, the air flow is also limited not too noticeably. The patient does not experience difficulties in everyday life, experiences shortness of breath only during active physical exertion, and a wet cough - only occasionally, with a high probability at night. At this stage, few people go to the doctor, usually because of other diseases.
• COPD 2 degree becomes more pronounced. Shortness of breath begins immediately when trying to engage in physical activity, cough appears in the morning, accompanied by a noticeable sputum discharge - sometimes purulent. The patient notices that he has become less hardy, and begins to suffer from recurring respiratory diseases - from a simple SARS to bronchitis and pneumonia. If the reason for going to the doctor is not suspicion of COPD, then sooner or later the patient still gets to him because of concomitant infections.
• COPD grade 3 is described as a difficult stage - if the patient has enough strength, he can apply for disability and confidently wait for a certificate to be issued to him. Shortness of breath appears even with minor physical exertion - up to climbing a flight of stairs. The patient is dizzy, dark in the eyes. Cough appears more often, at least twice a month, becomes paroxysmal in nature and is accompanied by chest pains. At the same time, the appearance is changing - rib cage expands, veins swell on the neck, the skin changes color either to cyanotic or pinkish. Body weight either sharply decreases or sharply decreases.
• Stage 4 COPD means that you can forget about any ability to work - the air flow entering the patient's lungs does not exceed thirty percent of the required volume. Any physical effort - up to changing clothes or hygiene procedures - causes shortness of breath, wheezing in the chest, dizziness. The breathing itself is heavy, labored. The patient has to constantly use an oxygen cylinder. In the worst cases, hospitalization is required.

However, in 2011, GOLD concluded that such criteria are too vague, and it is wrong to make a diagnosis solely on the basis of spirometry (which determines the volume of exhalation). Moreover, not all patients developed the disease sequentially, from a mild stage to a severe stage - in many cases, determining the stage of COPD was impossible. A CAT questionnaire was developed, which is filled in by the patient himself and allows you to determine the condition more fully. In it, the patient needs to determine, on a scale of one to five, how pronounced his symptoms are:

• cough - one corresponds to the statement "no cough", five "constantly";
• sputum - one is “no sputum”, five is “sputum is constantly coming out”;
• a feeling of tightness in the chest - “no” and “very strong”, respectively;
• shortness of breath - from "no shortness of breath at all" to "shortness of breath with the slightest exertion";
• household activity - from "without restrictions" to "very limited";
• leaving the house - from "confidently out of necessity" to "not even out of necessity";
• sleep - from "good sleep" to "insomnia";
• energy - from "full of energy" to "no energy at all."

The result is determined by scoring. If there are less than ten of them, the disease has almost no effect on the patient's life. Less than twenty, but more than ten - has a moderate effect. Less than thirty - has a strong influence. More than thirty - has a huge impact on life.

Objective indicators of the patient's condition, which can be recorded using instruments, are also taken into account. The main ones are oxygen tension and hemoglobin saturation. In a healthy person, the first value does not fall below eighty, and the second does not fall below ninety. In patients, depending on the severity of the condition, the numbers vary:

• with relatively mild - up to eighty and ninety in the presence of symptoms;
• in the course of moderate severity - up to sixty and eighty;
• in severe cases - less than forty and about seventy-five.

After 2011, according to GOLD, COPD no longer has stages. There are only degrees of severity, which indicate how much air enters the lungs. And the general conclusion about the patient’s condition does not look like “is at a certain stage of COPD”, but as “is in a certain risk group for exacerbations, adverse effects and death due to COPD”. There are four in total.

• Group A - low risk, few symptoms. A patient belongs to the group if he had no more than one exacerbation in a year, he scored less than ten points on CAT, and shortness of breath occurs only during exertion.
• Group B - low risk, many symptoms. The patient belongs to the group if there was no more than one exacerbation, but shortness of breath occurs frequently, and more than ten points were scored on CAT.
• Group C - high risk, few symptoms. The patient belongs to the group if he had more than one exacerbation per year, dyspnea occurs during exercise, and the CAT score is less than ten points.
• Group D - high risk, many symptoms. More than one exacerbation, shortness of breath occurs with the slightest exertion, and more than ten points on CAT.

The classification, although it was made in such a way as to take into account the condition of a particular patient as much as possible, still did not include two important indicators that affect the life of the patient and are indicated in the diagnosis. These are COPD phenotypes and comorbidities.

Phenotypes of COPD

In chronic obstructive pulmonary disease, there are two main phenotypes that determine how the patient looks and how the disease progresses.

bronchitis type:

• Cause. The cause of it is chronic bronchitis, relapses of which occur for at least two years.
• Changes in the lungs. The fluorography shows that the walls of the bronchi are thickened. On spirometry, it can be seen that the air flow is weakened and only partially enters the lungs.
• The classic age of discovery is fifty or older.
• Features of the patient's appearance. The patient has a pronounced cyanotic skin color, the chest is barrel-shaped, body weight usually grows due to increased appetite and may approach the border of obesity.
• The main symptom is a cough, paroxysmal, with abundant purulent sputum.
• Infections - often, because the bronchi are not able to filter the pathogen.
• Deformation of the heart muscle of the type "cor pulmonale" - often.

Cor pulmonale is a concomitant symptom in which the right ventricle enlarges and the heart rate accelerates - in this way the body tries to compensate for the lack of oxygen in the blood:

• X-ray. It can be seen that the heart is deformed and enlarged, and the pattern of the lungs is enhanced.
• Diffuse capacity of the lungs - that is, the time it takes for gas molecules to enter the blood. Normally, if it decreases, then not much.
• Forecast. According to statistics, the bronchitis type has a higher mortality rate.

The people call the bronchitis type "blue edema" and this is a fairly accurate description - a patient with this type of COPD is usually pale blue, overweight, coughs constantly, but is alert - shortness of breath does not affect him as much as patients with another type.

emphysematous type:

• Cause. The cause is chronic emphysema.
• Changes in the lungs. On fluorography, it is clearly seen that the partitions between the alveoli are destroyed and air-filled cavities are formed - bullae. With spirometry, hyperventilation is recorded - oxygen enters the lungs, but is not absorbed into the blood.
• The classic age of discovery is sixty or older.
• Features of the patient's appearance. sick different pink skin, the chest is also barrel-shaped, veins swell on the neck, body weight decreases due to decreased appetite and may approach the border of dangerous values.
• The main symptom is shortness of breath, which can be observed even at rest.
• Infections are rare, because the lungs still cope with filtering.
• Deformation of the type "cor pulmonale" is rare, the lack of oxygen is not so pronounced.
• X-ray. The picture shows the bullae and deformity of the heart.
• Diffuse ability - obviously greatly reduced.
• Forecast. According to statistics, this type has a longer life expectancy.

The emphysematous type is popularly called the “pink puffer” and this is also quite accurate: a patient with this type of hodl is usually thin, with an unnaturally pink skin color, constantly suffocates and prefers not to leave the house once again.

If a patient has signs of both types, they speak of a mixed COPD phenotype - it occurs quite often in a wide variety of variations. Also in recent years, scientists have identified several subtypes:

• with frequent exacerbations. It is set if the patient is sent to the hospital with exacerbations at least four times a year. Occurs in stages C and D.
• With bronchial asthma. Occurs in a third of cases - with all the symptoms of COPD, the patient experiences relief if he uses drugs to combat asthma. He also has asthma attacks.
• Early start. It is characterized by rapid progress and is explained by a genetic predisposition.
• At a young age. COPD is a disease of the elderly, but can also affect younger people. In this case, it is, as a rule, many times more dangerous and has a high mortality rate.

Concomitant diseases

With COPD, the patient has a great chance to suffer not only from the obstruction itself, but also from the diseases that accompany it. Among them:

• Cardiovascular disease, from coronary heart disease to heart failure. They occur in almost half of the cases and are explained very simply: with a lack of oxygen in the body, the cardiovascular system experiences heavy loads: the heart moves faster, blood flows faster through the veins, the lumen of the vessels narrows. After some time, the patient begins to notice chest pains, fluctuating pulse, headaches and increased shortness of breath. A third of patients whose COPD is accompanied by cardiovascular diseases die from them.
• Osteoporosis. Occurs in a third of cases. Not fatal, but very unpleasant and also provoked by a lack of oxygen. Its main symptom is bone fragility. As a result, the patient's spine is bent, posture deteriorates, the back and limbs hurt, night cramps in the legs and general weakness are observed. Decreased stamina, finger mobility. Any fracture heals for a very long time and can be fatal. Often there are problems with gastrointestinal tract- constipation and diarrhea, which are caused by the pressure of the curved spine on the internal organs.
• Depression. It occurs in almost half of the patients. Often its dangers remain underestimated, and meanwhile the patient suffers from decreased tone, lack of energy and motivation, suicidal thoughts, increased anxiety, feelings of loneliness and learning problems. Everything is seen in a gloomy light, the mood is constantly depressed. The reason is both the lack of oxygen and the impact that COPD has on the patient's life. Depression is not fatal, but it is difficult to treat and significantly reduces the pleasure that the patient could get from life.
• Infections. They occur in seventy percent of patients and cause death in a third of cases. This is explained by the fact that the lungs affected by COPD are very vulnerable to any pathogen, and it is difficult to remove inflammation in them. Moreover, any increase in sputum production is a decrease air flow and the risk of developing respiratory failure.
• Sleep apnea syndrome. With apnea, the patient stops breathing at night for longer than ten seconds. As a result, he suffers from constant oxygen starvation and may even die from respiratory failure.
• Crayfish. It occurs frequently and causes death in one out of five cases. It is explained, like infections, by the vulnerability of the lungs.

In men, COPD is often accompanied by impotence, and in the elderly it causes cataracts.

Diagnosis and disability

The formulation of the diagnosis of COPD implies a whole formula that doctors follow:

1. the name of the disease is chronic lung disease;
2. COPD phenotype - mixed, bronchitis, emphysematous;
3. the severity of bronchial obstruction - from mild to extremely severe;
4. severity of COPD symptoms - determined by CAT;
5. frequency of exacerbations - more than two frequent, less rare;
6. accompanying illnesses.

As a result, when the examination is completed according to the plan, the patient receives a diagnosis that sounds, for example, like this: “chronic obstructive pulmonary disease of the bronchitis type, II degree of bronchial obstruction with severe symptoms, frequent exacerbations, aggravated by osteoporosis.”

Based on the results of the examination, a treatment plan is drawn up and the patient can apply for disability - the more severe the COPD, the more likely it is that the first group will be delivered.

And although COPD is not treated, the patient must do everything in his power to maintain his health at a certain level - and then both the quality and duration of his life will increase. The main thing is to remain optimistic in the process and not to neglect the advice of doctors.

January 27, 2017 The new COPD Global Strategy for Diagnosis, Treatment and Prevention (GOLD) Working Group Report 2017 was released, a collaborative effort of 22 experts in the field of chronic obstructive pulmonary disease (COPD). This report is based on scientific publications on this issue that were published up to October 2016. It was simultaneously published online in the American Journal of Respiratory and Critical Care Medicine and hosted on the GOLD website. The updated guidelines review recent developments in diagnosis, de-escalation strategies, non-pharmacological treatment options, and the role of comorbidities in the management of patients with COPD.

As before, the new report recommends screening for COPD in patients with a history of COPD risk factors and those with shortness of breath, chronic cough, or sputum production. In this case, as a diagnostic criterion, it is recommended to use the ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) after inhalation of a bronchodilator equal to< 0,70. Факторами риска развития ХОБЛ считаются отягощенный семейный анамнез, низкая масса тела при рождении, частые респираторные инфекции в детстве, а также воздействие табачного дыма, дыма от сгорания топлива, которое используется для обогрева или приготовления пищи, а также ряд профессиональных воздействий, например, пыли, паров, копоти и прочих химических факторов.

One of the key changes in the new document is the separation of symptom assessment from spirometry assessment. Although pulmonary function testing remains necessary for diagnosis, the main goals of the examination are to assess symptoms, risk of exacerbations, and the degree of impact of the disease on the general health of patients. Based on these parameters, patients can then be classified into groups A, B, C and D, according to which treatment is prescribed. Thus, spirometry remains a diagnostic tool and a marker of the severity of obstruction, but it is no longer needed for pharmacotherapy decisions, with the exception of prescribing roflumilast. Also, threshold values ​​determined by spirometry remain relevant for non-pharmacological treatments, in particular for lung volume reduction and lung transplantation.

Another change concerns the definition of aggravation, which is now formulated in a simpler and more practical way. The evidence base for the treatment of exacerbation prevention was also supplemented.

Another new aspect of the GOLD Report is a detailed discussion of treatment intensification and de-escalation strategies, while earlier reports have mainly focused on initial therapy recommendations. Along with the inclusion of treatment amplification and de-intensification algorithms, the experts modified the discussion of treatment options and removed the first line from alternative therapy options. The document now includes additional rationale for recommended initial therapy and possible alternatives for all patient categories (ABCD). The guidelines also place a lot of emphasis on the use of combined bronchodilators as the first line of treatment.

The updated guidance also provides a detailed analysis of non-pharmacological treatment options beyond influenza and pneumococcal vaccination to reduce the risk of lower respiratory tract infections. Smoking cessation remains the most important aspect of any treatment plan, and pulmonary rehabilitation is a highly beneficial intervention. The latter is understood as a complex intervention based on a thorough assessment of the patient's condition and adapted to his needs. It may include such components as physical training, education (including self-help), interventions aimed at achieving behavioral changes in order to improve physical and psychological state and to improve adherence to treatment. Pulmonary rehabilitation has the potential to reduce the risk of readmissions and mortality in patients after a recent exacerbation, but there is evidence that its initiation before the patient's discharge may lead to an increase in mortality.

Oxygen inhalation may improve survival in patients with severe resting hypoxemia, but long-term oxygen therapy in individuals with stable COPD and moderate or exercise-only hypoxemia does not prolong life expectancy or reduce the risk of hospitalization. The usefulness of assisted ventilation remains unclear, although patients with proven obstructive sleep apnea should use continuous positive airway pressure machines to increase survival and reduce the risk of hospitalization.

As mentioned above, an important part of the new document is devoted to the diagnosis and treatment of comorbidities in patients with COPD. In addition to the importance of identifying and treating obstructive sleep apnea, discussed above, the GOLD Report talks about the importance of awareness of comorbid cardiovascular diseases, osteoporosis, anxiety and depression, gastroesophageal reflux, and their adequate treatment.

Compared to previous reports, surgical techniques that have proven to be effective, such as lung volume reduction surgery, bullectomy, lung transplantation, and some bronchoscopic interventions, are discussed in more detail. All should be considered in selected patients with appropriate indications.

The section on palliative care has also become more detailed. Discusses hospice care and other end-of-life issues, as well as optimal strategies for managing symptoms such as shortness of breath, pain, anxiety, depression, fatigue, and malnutrition.

In principle, new GOLD reports are published annually as needed, but the text undergoes significant changes only once every few years as a significant amount of new information accumulates, which must be taken into account in clinical practice. This update is the result of another planned major revision, and the authors hope that as a result of their work, the guidelines will be more practical and easier to use in a variety of clinical situations.

Chronic obstructive pulmonary disease (COPD) is a generally preventable and treatable disease characterized by permanent airflow limitation that is usually progressive and associated with an increased chronic inflammatory response of the airways and lungs in response to exposure to noxious particles and gases. Exacerbations and concomitant diseases contribute to a more severe course of the disease.

This definition of the disease is preserved in the document of an international organization that refers to itself as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and constantly monitors this problem, and also presents its annual documents to doctors. The latest GOLD-2016 update has been reduced in size and has a number of additions that we will discuss in this article. In Russia, most of the provisions of GOLD are approved and implemented in national clinical guidelines.

Epidemiology

The problem of COPD is a significant public health problem and will remain so as long as the proportion of the population who smokes remains high. A separate problem is COPD in non-smokers, when the development of the disease is associated with industrial pollution, unfavorable working conditions in both urban and rural areas, contact with fumes, metals, coal, other industrial dusts, chemical fumes, etc. All this leads to consideration of the COPD variant as an occupational disease. According to the Central Research Institute of Health Organization and Informatization of the Ministry of Health in Russian Federation the incidence of COPD from 2005 to 2012 increased from 525.6 to 668.4 per 100 thousand of the population, i.e., the growth dynamics was more than 27%.

The website of the World Health Organization presents the structure of causes of death over the past 12 years (2010-2012), in which COPD and lower respiratory tract infections share 3rd-4th place, and in total actually come out on top. However, when countries are divided according to the income level of the population, this position changes. In low-income countries, people do not live to see the end stages of COPD and die from lower respiratory tract infections, HIV-related conditions, and diarrhea. COPD is not among the top ten causes of death in these countries. In countries with high per capita income, COPD and lower respiratory tract infections are tied for 5-6 places, and the leaders are ischemic disease heart and stroke. With an income above average, COPD ranked third in the causes of death, and below average - in 4th. In 2015, a systematic analysis was conducted of 123 publications on the prevalence of COPD in the population aged 30 years and over in the world from 1990 to 2010. During this period, the prevalence of COPD increased from 10.7% to 11.7% (or from 227.3 million to 297 million COPD patients). The largest increase in the indicator was among Americans, the smallest in Southeast Asia. Among urban residents, the prevalence of COPD increased from 13.2% to 13.6%, and among rural residents - from 8.8% to 9.7%. Among men, COPD occurred almost 2 times more often than among women - 14.3% and 7.6%, respectively. For the Republic of Tatarstan, COPD is also an urgent problem. As of the end of 2014, 73,838 patients with COPD were registered in Tatarstan, the mortality rate was 21.2 per 100,000 population, and the mortality rate was 1.25%.

The unfavorable dynamics of the epidemiology of COPD was stated despite the great progress in clinical pharmacology bronchodilators and anti-inflammatory drugs. Along with improving the quality, selectivity of action, new drugs are becoming more expensive, significantly increasing the economic and social burden of COPD for the healthcare system (according to expert estimates of the Public Foundation "Quality of Life", the economic burden of COPD for the Russian Federation in 2013 prices was estimated at more than 24 billion rubles, while almost 2 times the economic burden bronchial asthma) .

Evaluation of epidemiological data on COPD is difficult for a number of objective reasons. First of all, until recently, in the ICD-10 codes, this nosology was in the same column as bronchiectasis. In the updated version of the classification, this position has been eliminated, but it should become legislatively fixed and coordinated with the statisticians of the Ministry of Health of the Russian Federation, Roszdravnadzor, Rospotrebnadzor and Rosstat. This position has not yet been implemented, which has a negative impact on volume forecasting medical care and budgeting of MHI funds.

Clinic and diagnostics

COPD is a preventable condition because its causes are well known. The first is smoking. In the latest edition of GOLD, along with smoking, occupational dust and chemical exposures, indoor air pollution from cooking and heating (especially among women in developing countries) are classified as COPD risk factors.

The second problem is that the criterion for the definitive diagnosis of COPD is the presence of data on forced expiratory spirometry after a test with a short-acting bronchodilator. clear and secure a wide range equipment procedure - spirometry has not received proper distribution and accessibility in the world. But even with the availability of the method, it is important to control the quality of the recording and interpretation of the curves. It should be noted that according to the GOLD of the last revision, spirometry is necessary for making a definitive diagnosis of COPD, whereas previously it was used to confirm the diagnosis of COPD.

Comparison of symptoms, complaints and spirometry in COPD diagnosis is the subject of research and additions to the manual. On the one hand, a recently published study of the prevalence of broncho-obstructive syndrome in northwestern Russia showed that the prognostic value of symptoms does not exceed 11%.

At the same time, it is extremely important to emphasize doctors, especially therapists, doctors general practice and family medicine doctors, for the presence characteristic symptoms COPD in order to timely identify these patients and carry out their correct further routing. The latest revision of GOLD noted that "cough and sputum production are associated with increased mortality in patients with mild to moderate COPD", and COPD assessment is based on the severity of symptoms, the risk of future exacerbations, the severity of spirometry disorders and the identification of comorbidities.

Regulations on the interpretation of spirometry in COPD are being improved year by year. The absolute value of the FEV1/FVC ratio can lead to overdiagnosis of COPD in older people, since the normal aging process leads to a decrease in lung volumes and flows, and can also lead to underdiagnosis of COPD in people under 45 years of age. GOLD experts noted that the concept of determining the degrees of impairment only on the basis of FEV 1 is not accurate enough, but there is no alternative system. The most severe degree of spirometry disorders GOLD 4 does not include a reference to the presence of respiratory failure. In this regard, the modern balanced position for assessing patients with COPD, both in terms of clinical assessment and according to spirometric criteria, to the greatest extent meets the requirements of real life. clinical practice. The decision on treatment is recommended to be made based on the impact of the disease on the patient's condition (symptoms and limitation of physical activity) and the risk of future disease progression (especially the frequency of exacerbations).

It should be noted that an acute test with short-acting bronchodilators (salbutamol, fenoterol, fenoterol/ipratropium bromide) is recommended both through metered-dose aerosol inhalers (PMIs) and during nebulization of these drugs. The values ​​of FEV 1 and FEV 1 /FVC after bronchodilator are decisive for the diagnosis of COPD and the assessment of the degree of spirometric disorders. At the same time, it is recognized that the bronchodilator test has lost its leading position both in differential diagnosis bronchial asthma and COPD, and in predicting the effectiveness of the subsequent use of bronchodilators long-acting.

Since 2011, it has been recommended to divide all patients with COPD into ABCD groups based on three coordinates - spirometric gradations according to GOLD (1-4), frequency of exacerbations (or one hospitalization) during last year and responses to standardized questionnaires (CAT, mMRC or CCQ). A corresponding table has been created, which is also presented in the GOLD revision 2016. Unfortunately, the use of questionnaires remains a priority in those medical centers, where active epidemiological and clinical studies are carried out, while in general clinical practice in public institutions Health care assessment of patients with COPD using CAT, mMRC or CCQ for a variety of reasons is the exception rather than the rule.

Russian federal recommendations for the diagnosis and treatment of COPD reflect all the criteria proposed by GOLD, but include them in medical documentation when describing COPD is not yet necessary. According to domestic recommendations, the diagnosis of COPD is built as follows:

“Chronic obstructive pulmonary disease…” followed by an assessment of:

• severity (I-IV) violation of bronchial patency;
• expressiveness clinical symptoms: pronounced (CAT ≥ 10, mMRC ≥ 2, CCQ ≥ 1), not expressed (CAT< 10, mMRC < 2, CCQ < 1);
• exacerbation rates: rare (0-1), frequent (≥ 2);
• COPD phenotype (if possible);
• concomitant diseases.

When conducting research and comparing foreign publications on COPD until 2011 and later, it should be understood that the division of COPD according to spirometric criteria 1-4 and ABCD groups is not identical. The most unfavorable variant of COPD - GOLD 4 does not fully correspond to type D, since the latter can have both patients with signs of GOLD 4, and with a large number of exacerbations over the past year.

COPD management is one of the most dynamic areas of guidance and advice. The approach to treatment begins with the elimination of the damaging agent - stopping smoking, changing hazardous work, improving ventilation in rooms, etc.

It is important that everyone recommend quitting smoking medical workers. Compromise of one doctor in the chain of contacts of a COPD patient can have irreversible consequences- the patient will remain a smoker and thereby worsen the prognosis of his life. Currently, drug methods for quitting smoking have been developed - nicotine replacement and blocking dopamine receptors (depriving the patient of the “pleasure of smoking”). In any case, the decisive role is played by the volitional decision of the patient himself, the support of relatives and the reasoned recommendations of the medical worker.

It has been proven that COPD patients should lead the most physically active lifestyle possible, and special fitness programs have been developed. Physical activity is also recommended for the rehabilitation of patients after exacerbations. The physician should be aware of the possibility of developing depression in patients with severe COPD. GOLD experts regard depression as a risk factor for the ineffectiveness of rehabilitation programs. To prevent infectious exacerbations of COPD, seasonal influenza vaccination is recommended, and after 65 years - pneumococcal vaccination.

Therapy

Treatment of COPD is determined by the periods of the disease - a stable course and exacerbation of COPD.

The doctor must clearly understand the tasks of managing a patient with stable COPD. It should relieve symptoms (shortness of breath and cough), improve tolerance physical activity(the patient must be able to at least care for himself). It is necessary to reduce the risk to which a patient with COPD is exposed: to slow down the progression of the disease as much as possible, prevent and treat exacerbations in a timely manner, reduce the likelihood of death, influence the quality of life of patients and the frequency of relapses of the disease. Long-acting inhaled bronchodilators should be preferred over short-acting inhaled and oral agents. However, it should be taken into account that for more than 30 years it has been successfully used in clinical practice and is included in domestic standards of therapy and clinical guidelines a combination of ipratroprium bromide with fenoterol (table, preparations 1 and 2) in the form of PDI and a solution for nebulizer therapy.

Olodaterol has been added to the latest revision of the GOLD document. Earlier in this list were formoterol (table, preparation 3), tiotropium bromide, aclidinium bromide, glycopyrronium bromide, indacaterol. Among them are drugs with beta2-adrenomimetic (LABA) and M3-anticholinergic (LAHA) effects. Each of them has shown its effectiveness and safety in large randomized trials, but the latest generation of drugs is a fixed combination of long-acting bronchodilators with different mechanisms bronchial dilatation (indacaterol / glycopyrronium, olodaterol / tiotropium bromide, vilanterol / umeclidinium bromide).

The combination of long-acting drugs on a permanent basis and short-acting drugs on demand is allowed by GOLD experts if drugs of the same type are insufficient to control the patient's condition.

At the same time, the latest up-to-date list of vital and essential medicines for medical use(Vital and Essential Drugs) for 2016, only three selective beta2-adrenergic agonists were included in the monoform, including salbutamol (table, preparation 5) and formoterol (table, preparation 3) and three anticholinergics, including ipratropium bromide (table, preparation 7 and 8).

When choosing a bronchodilator, it is extremely important to appoint a drug delivery device that is understandable and convenient for the patient, and he will not make mistakes when using it. Almost every new drug has a newer and more advanced delivery system (especially for powder inhalers). And each of these inhalation devices has its strengths and weaknesses.

Prescribing oral bronchodilators should be the exception to the rule, their use (including theophylline) is accompanied by a higher frequency of adverse drug reactions without advantages in bronchodilatory effect.

The test with short-acting bronchodilators has long been considered a strong argument for the appointment or non-appointment of regular bronchodilator therapy. The latest edition of GOLD noted the limited predictive value of this test, and the effect of long-acting drugs during the year does not depend on the result of this test.

Over the past three decades, the attitude of doctors to the use of inhaled glucocorticosteroids (iGCS) has changed. At first, there was extreme caution, then the use of inhaled corticosteroids was practiced in all patients with FEV1 less than 50% of the expected values, and now their use is limited to certain COPD phenotypes. If in the treatment of bronchial asthma, inhaled corticosteroids form the basis of basic anti-inflammatory therapy, then in COPD, their appointment requires strong justification. According to the modern concept, inhaled corticosteroids are recommended for stage 3-4 or for types C and D according to GOLD. But even at these stages and types in the emphysematous phenotype of COPD with rare exacerbations, the effectiveness of inhaled corticosteroids is not high.

In the latest edition of GOLD, it is noted that the abolition of ICS in patients with COPD with a low risk of exacerbations can be safe, but they should definitely leave long-acting bronchodilators as basic therapy. The single-dose iGCS/LABA combination did not show significant differences in efficacy compared to two-dose administration. In this regard, the use of inhaled corticosteroids is justified in the combination of bronchial asthma and COPD (phenotype with a crossover of two diseases), in patients with frequent exacerbations and FEV1 less than 50% of due. One of the criteria for the effectiveness of inhaled corticosteroids is an increase in the number of eosinophils in the sputum of a patient with COPD. A factor that causes reasonable caution when using inhaled corticosteroids in COPD is the increase in the incidence of pneumonia associated with an increase in the dose of inhaled steroid. On the other hand, the presence of severe emphysema indicates a low prospect of inhaled corticosteroids due to the irreversibility of the disorders and the minimal inflammatory component.

All these considerations do not in the least detract from the expediency of using fixed combinations of iGCS / LABA in COPD with indications. Long-term iGCS monotherapy in COPD is not recommended, since it is less effective than the combination of iGCS / LABA, and is associated with an increased risk of developing infectious complications (purulent bronchitis, pneumonia, tuberculosis) and even an increase in bone fractures. Such fixed combinations as salmeterol + fluticasone (Table, drug 4) and formoterol + budesonide have not only a large evidence base in randomized clinical trials, but also confirmation in real clinical practice in the treatment of patients with GOLD stage 3-4 COPD.

Systemic glucocorticosteroids (sGCS) are not recommended in stable COPD, since their long-term use causes serious adverse drug reactions, sometimes comparable in severity to the underlying disease, and short courses without exacerbation do not have a significant effect. The doctor must understand that the appointment of glucocorticosteroids on an ongoing basis is a therapy of desperation, a recognition that all other safer therapy options have been exhausted. The same applies to the use of parenteral depot steroids.

For patients with severe COPD with frequent exacerbations, with a bronchitis phenotype of the disease, in whom the use of LABA, LAAA and their combinations does not give the desired effect, phosphodiesterase-4 inhibitors are used, among which only roflumilast is used in the clinic (once a day orally).

Exacerbation of COPD is a key negative event during this chronic disease, which adversely affects the prognosis in proportion to the number of repeated exacerbations during the year and the severity of their course. A COPD exacerbation is an acute condition characterized by worsening respiratory symptoms in a patient that goes beyond the daily normal fluctuations and leads to a change in the therapy used. The importance of COPD in worsening the condition of patients should not be overestimated. Acute conditions such as pneumonia, pneumothorax, pleurisy, thromboembolism, and the like in a patient with chronic dyspnoea should be excluded when the physician suspects an exacerbation of COPD.

When evaluating a patient with signs of exacerbation of COPD, it is important to determine the main direction of therapy - antibiotics for infectious exacerbation of COPD and bronchodilators / anti-inflammatory drugs for an increase in broncho-obstructive syndrome without indications for antibiotics.

Most common cause exacerbation of COPD is viral infection upper respiratory tract, trachea and bronchi. An exacerbation is recognized both by an increase in respiratory symptoms (shortness of breath, cough, amount and purulence of sputum) and by an increase in the need for short-acting bronchodilators. However, the reasons for the exacerbation may also be the resumption of smoking (or other pollution of the inhaled air, including industrial ones), or irregularities in the regularity of ongoing inhalation therapy.

In the treatment of exacerbations of COPD, the main task is to minimize the impact of this exacerbation on the subsequent condition of the patient, which requires rapid diagnosis and adequate therapy. Depending on the severity, it is important to determine the possibility of treatment on an outpatient basis or in a hospital (or even in a ward). intensive care). Particular attention should be paid to patients who had exacerbations in past years. Currently, patients with frequent exacerbations are considered as a persistent phenotype, among them the risk of subsequent exacerbations and worsening of the prognosis is higher.

It is necessary to assess the saturation and state of blood gases during the initial examination, and in case of hypoxemia, immediately begin low-flow oxygen therapy. In extremely severe COPD, non-invasive and invasive ventilation is used.

Universal first aid drugs are short-acting bronchodilators - beta2-agonists (salbutamol (table, preparation 5), fenoterol (table, preparation 5)) or their combinations with anticholinergics (ipratropium bromide (table, preparation 7 and 8)) . In the acute period, the use of drugs through any PDI, including with a spacer, is recommended. The use of drug solutions in the acute period by delivery through nebulizers of any type (compressor, ultrasonic, mesh nebulizers) is more appropriate. The dose and frequency of application are determined by the patient's condition and objective data.

If the patient's condition allows, then prednisolone is prescribed orally at a dose of 40 mg per day for 5 days. Oral corticosteroids in the treatment of exacerbations of COPD lead to improvement in symptoms, lung function, decrease in the likelihood of treatment failure for exacerbations, and shorten the duration of hospitalization during exacerbations. Systemic corticosteroids in the treatment of exacerbations of COPD may reduce the frequency of hospitalizations due to recurrent exacerbations within the next 30 days. Intravenous administration is indicated only in the intensive care unit, and only until the moment when the patient can take the drug inside.

After a short course of glucocorticosteroids (or without it), with a moderate exacerbation, nebulization of iGCS is recommended - up to 4000 mcg per day of budesonide active substance in suspension, and it is not advisable to inhale suspensions through a membrane (mesh) nebulizer, since there is a serious possibility of clogging the miniature holes of the nebulizer membrane with a suspension, which will lead, on the one hand, to a shortfall in the therapeutic dose, and on the other hand, to a malfunction of the nebulizer membrane and the need to replace it ). An alternative may be a budesonide solution (table, preparation 9), developed and manufactured in Russia, which is compatible with any type of nebulizer, which is convenient for both inpatient and outpatient use.

Indications for the use of antibiotics in COPD are increased shortness of breath and cough with purulent sputum. Sputum purulence is a key criterion for prescribing antibacterial agents. GOLD experts recommend aminopenicillins (including those with beta-lactamase inhibitors), new macrolides and tetracyclines (in Russia there is a high level of resistance of respiratory pathogens to them). At high risk or obvious seeding of Pseudomonas aeruginosa from the sputum of a COPD patient, treatment is focused on this pathogen (ciprofloxacin, levofloxacin, antipseudomonal beta-lactams). In other cases, antibiotics are not indicated.

Comorbidities in COPD are covered in Chapter 6 of the latest edition of GOLD. The most common and important comorbidities are ischemic heart disease, heart failure, atrial fibrillation and hypertension. Treatment of cardiovascular diseases in COPD does not differ from their treatment in patients without COPD. It is especially noted that among beta1-blockers, only cardioselective drugs should be used.

Osteoporosis also often accompanies COPD, and COPD treatment (systemic and inhaled steroids) can reduce bone density. This makes the diagnosis and treatment of osteoporosis in COPD an important component in the management of patients.

Anxiety and depression worsen the prognosis of COPD, complicate the rehabilitation of patients. They are more common in younger patients with COPD, in women, with a pronounced decrease in FEV1, with a pronounced cough syndrome. The treatment of these conditions also does not have features in COPD. Physical activity, fitness programs can play a positive role in the rehabilitation of patients with anxiety and depression in COPD.

Lung cancer is common in COPD patients and is the most common cause of death in non-severe COPD patients. Respiratory tract infections are common in COPD and cause exacerbations. Inhaled steroids used in severe COPD increase the chance of developing pneumonia. Repeated infectious exacerbations of COPD and concomitant infections in COPD increase the risk of developing antibiotic resistance in this group of patients due to the appointment of repeated courses of antibiotics.

Treatment of metabolic syndrome and diabetes in COPD is carried out in accordance with existing recommendations for the treatment of these diseases. The factor that increases this type of comorbidity is the use of sGCS.

Conclusion

The work of doctors to keep patients in contingents of additional drug provision is extremely important. The refusal of citizens from this initiative in favor of monetization of benefits leads to a decrease in the potential costs of medicines for patients who remain committed to the benefit. Linking levels of drug provision with clinical diagnosis (COPD or bronchial asthma) contributes both to statistical distortions and unreasonable costs in the current system of drug provision.

In a number of regions of Russia, there has been a “staff shortage” in pulmonologists and allergists, which is a significant unfavorable factor in relation to the possibility of providing qualified medical care to patients with obstructive bronchopulmonary diseases. In a number of regions of Russia, there is a general reduction in the number of beds. At the same time, the existing "pneumological beds" are also undergoing a process of reprofiling to provide medical care in other therapeutic areas. Along with this, the reduction in the number of beds in the pulmonology profile is often not accompanied by an adequate proportional provision of outpatient and inpatient care.

An analysis of real clinical practice in Russia indicates a lack of adherence of physicians in their appointments to the accepted standards of COPD management. The transition of patients to self-sufficiency with drugs leads to a decrease in adherence to treatment, irregular use of drugs. Asthma and COPD schools, which are not organized on a regular basis in all regions of the Russian Federation, have become one of the ways to increase adherence to therapy.

Thus, COPD is a very common disease in the world and the Russian Federation, which creates a significant burden on the healthcare system and the country's economy. Diagnosis and treatment of COPD are constantly improving, and the main factors that maintain the high prevalence of COPD in the population of people in the second half of life are the unrelenting number of people who smoke for 10 years or more and harmful production factors. A significant worrying aspect is the lack of downward dynamics in mortality, despite the emergence of more and more new drugs and delivery vehicles. The solution to the problem may consist in increasing the availability of drug provision for patients, which should be maximally facilitated by the state import substitution program, in timely diagnosis and increasing patient adherence to the prescribed therapy.

Literature

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD): Updated 2016. 80 p.
2. Chuchalin A. G., Avdeev S. N., Aisanov Z. R., Belevsky A. S., Leshchenko I. V., Meshcheryakova N. N., Ovcharenko S. I., Shmelev E. I. Russian respiratory society. Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease // Pulmonology, 2014; 3:15-54.
3. Zinchenko V. A., Razumov V. V., Gurevich E. B. Occupational chronic obstructive pulmonary disease (COPD) is a missing link in the classification of occupational lung diseases (critical review). In: Clinical aspects of occupational pathology / Ed. Doctor of Medical Sciences, Professor V. V. Razumov. Tomsk, 2002, pp. 15-18.
4. Danilov A.V. Comparison of the incidence of COPD among workers of an agricultural enterprise, an industrial enterprise of the city of Ryazan and the urban population // Science of the Young - Eruditio Juvenium. 2014. No. 2. S. 82-87.
5. Starodubov V. I., Leonov S. A., Vaysman D. Sh. Analysis of the main trends in the incidence of chronic obstructive pulmonary disease and bronchiectasis in the Russian Federation in 2005-2012 // Medicine. 2013. No. 4. S. 1-31.
6. http://www.who.int/mediacentre/factsheets/ fs310/en/index.html (Accessed 01/17/2016).
7. Adeloye D., Chua S., Lee C., Basquill C., Papana A., Theodoratou E., Nair H., Gasevic D., Sridhar D., Campbell H., Chan K. Y., Sheikh A., Rudan I. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis // J. Glob. health. 2015; 5(2): 020415.
8. Vafin A. Yu., Vizel A. A., Sherputovsky V. G., Lysenko G. V., Kolgin R. A., Vizel I. Yu., Shaimuratov R. I., Amirov N. B. Respiratory diseases in the Republic of Tatarstan: long-term epidemiological analysis // Bulletin of modern clinical medicine. 2016. V. 9, No. 1. S. 24-31.
9. Perez-Padilla R. Would widespread availability of spirometry solve the problem of underdiagnosis of COPD? // Int. J. Tuberc. lung dis. 2016; 20(1):4.
10. Marquez-Martin E., Soriano J. B., Rubio M. C., Lopez-Campos J. L. 3E project. Differences in the use of spirometry between rural and urban primary care centers in Spain // Int. J. Chron. obstruct. Pulmon. Dis. 2015; 10:1633-1639.
11. Andreeva E., Pokhaznikova M., Lebedev A., Moiseeva I., Kutznetsova O., Degryse J. M. The prevalence of Chronic Obstructive Pulmonary Disease by the Global Lung Initiative equations in North-Western Russia // Respiration. 2016 Jan 5. .
12. Ovcharenko S.I. Chronic obstructive pulmonary disease: the real situation in Russia and ways to overcome it // Pulmonology. 2011. No. 6. S. 69-72.
13. Aisanov Z. R., Chernyak A. V., Kalmanova E. N. Spirometry in the diagnosis and evaluation of therapy for chronic obstructive pulmonary disease in general practice // Pulmonology. 2014; 5:101-108.
14. Haughney J., Gruffydd-Jones K., Robert J. et al. The distribution of COPD in UK general practice using the new GOLD classification // Eur. Respir. J. 2014; 43(4): 993-10-02.
15. Gnatyuk O.P. The impact of health care staffing Khabarovsk Territory on morbidity rates chronic bronchitis and chronic obstructive pulmonary disease // Bulletin of Public Health and Healthcare of the Far East of Russia. 2011. No. 2. S. 1-10.
16. Research project of the Quality of Life Foundation: "Socio-economic losses from bronchial asthma and chronic obstructive pulmonary disease in the Russian Federation", 2013.
17. Decree of the Government of the Russian Federation of December 26, 2015 No. 2724-r On approval of the list of vital and essential drugs for medical use for 2016.

A. A. Wiesel 1 ,doctor of medical sciences, professor
I. Yu. Wiesel, Candidate of Medical Sciences

GBOU VPO KSMU Ministry of Health of the Russian Federation, Kazan

* The drug is not registered in the Russian Federation.

** For state and municipal needs, the priority of drug provision of patients with domestic drugs and the restriction on the admission of purchases of drugs originating from foreign countries are determined by Decree of the Government of the Russian Federation dated November 30, 2015 No. 1289.